Review
doi: 10.1016/s0094-0143(05)70238-x.
The potential role of gene therapy in the treatment of bladder cancer
Affiliations
- PMID: 10696249
- DOI: 10.1016/s0094-0143(05)70238-x
Item in Clipboard
Review
The potential role of gene therapy in the treatment of bladder cancer
Urol Clin North Am.
2000 Feb.
Abstract
Based on understanding the molecular mechanism of bladder carcinogenesis, cancer gene therapy may well become a novel therapy in the near future. Currently, a viral vector system appears to be a better vehicle to deliver genes into target cells. Exploring different therapeutic strategies has generated promising results from preclinical bladder cancer models. Phase I clinical trials are underway to study the feasibility of this treatment for human bladder cancer patients. However, several potential problems associated with effective gene delivery need to be further refined.
Similar articles
-
Gene therapy for bladder cancer.World J Urol. 2000 Apr;18(2):148-51. doi: 10.1007/s003450050188. World J Urol. 2000. PMID: 10854151 Review.
-
Therapeutic approaches to bladder cancer: identifying targets and mechanisms.Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S67-83. doi: 10.1016/s1040-8428(03)00066-0. Crit Rev Oncol Hematol. 2003. PMID: 12850529 Review.
-
Gene therapy: the challenges of translating laboratory research into clinical practice.J Clin Oncol. 2003 Jun 15;21(12):2230-1. doi: 10.1200/JCO.2003.92.042. J Clin Oncol. 2003. PMID: 12805319 No abstract available.
-
The genetics of transitional cell carcinoma: progress and potential clinical application.BJU Int. 1999 Sep;84(4):412-27. doi: 10.1046/j.1464-410x.1999.00217.x. BJU Int. 1999. PMID: 10468754 Review. No abstract available.
-
Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.J Clin Oncol. 2003 Jun 15;21(12):2247-53. doi: 10.1200/JCO.2003.09.138. J Clin Oncol. 2003. PMID: 12805322 Clinical Trial.
Cited by
-
Targeting gene expression of the mouse uroplakin II promoter to human bladder cells.Urol Res. 2003 Mar;31(1):17-21. doi: 10.1007/s00240-002-0294-x. Epub 2003 Feb 18. Urol Res. 2003. PMID: 12624658
-
Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder Cancer.Sci Rep. 2017 Jun 9;7(1):3172. doi: 10.1038/s41598-017-03421-5. Sci Rep. 2017. PMID: 28600516 Free PMC article.
-
Localized bladder cancer.Curr Treat Options Oncol. 2000 Dec;1(5):423-32. doi: 10.1007/s11864-000-0070-5. Curr Treat Options Oncol. 2000. PMID: 12057150 Review.
-
Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model.Oncol Lett. 2011 Jan;2(1):13-19. doi: 10.3892/ol.2010.217. Epub 2010 Nov 23. Oncol Lett. 2011. PMID: 22870122 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
